The JAK2-STAT3 pathway is frequently constitutively activated in various cancers, including breast (K Banerjee and H Resat 2016), gastric (Kanda et al. 2004), prostate (Ni et al. 2000), and pancreatic cancer (Lian et al. 2004), leading to tumor progression, survival, treatment resistance, metastasis, and immune evasion (Hu et al. 2024). This evidence concerns the gene JAK2 and cancer.